MAIN CONFERENCE 12/18 - PT (Pacific Time, GMT-08:00)
MAIN CONFERENCE 12/18 - PT (Pacific Time, GMT-08:00)
On Demand
Fun Run on San Diego Harbor- Meet in Marriott Marquis Foyer
7:15am - 7:30am15 mins
Registration
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #1
Electron Density Topography (EDT): A Way for On-demand 3D Observation of Therapeutic Molecules in Solution, From Small Proteins up to Delivery Particles
- Takashi Sato, PhD - Chief Scientist & Technical Architect, Life Science Product Division, Rigaku Corporation
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #2
Global Bio
8:10am - 8:15am5 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Co-Chairs’ Remarks - Emerging In Vitro Approaches to Antibody Discovery
- Paul Parren, PhD - Founder and CSO, Gyes BV
- Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
8:10am - 8:15am5 mins
Track 2: Unusual Antibody Formats
Co-Chairs’ Remarks - Unusual Antibody Formats
- Sally Ward, PhD - Professor and Director, University of Southampton
- Karen Silence, PhD - Head Preclinical Product Development, Argenx
8:15am - 8:45am30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Direct Selection of Functional Antibodies and/or VHHs
- Sarah Ives - Vice President, Biopharma, Triplebar Bio
- Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
8:15am - 8:45am30 mins
Track 2: Unusual Antibody Formats
Engineered Multispecific Immunoglobulin/Single-domain Antibody Fusion Proteins As Novel Immunotherapeutics
- Jamie Spangler, PhD - Associate Professor, Johns Hopkins University
8:45am - 9:15am30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Overcoming the Membrane Mountain: Roadmap to Biotherapeutic Discovery Against Complex Membrane Targets Using Next-Gen Antibody and Antibody Fragment Libraries
- Jeff Barker, Ph.D. - Principal Research Scientist I, AbbVie Bioresearch Center
8:45am - 9:15am30 mins
Track 2: Unusual Antibody Formats
Applications of Cow Ultralong CDR3 Knobs as the Smallest Antibody Fragment
- Vaughn Smider, MD, PhD - Adjunct Professor, Molecular Medicine, The Scripps Research Institute
9:15am - 9:45am30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Fast Track Discovery of Human B Cell-derived Antibodies by Direct Functional Screening
- Christoph Esslinger, Ph.D. - CSO, Memo Therapeutics
9:15am - 9:45am30 mins
Track 2: Unusual Antibody Formats
KnotBodies; Creating Ion Channel Modulating Antibodies by Fusing Knottins into Antibody Loops
- Aneesh Karatt Vellatt, PhD - Chief Scientific Officer, Maxion Therapeutics
9:45am - 10:30am45 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Networking Refreshment Break, Exhibit and Poster Viewing
9:45am - 10:30am45 mins
Track 2: Unusual Antibody Formats
Networking Refreshment Break, Exhibit and Poster Viewing
10:30am - 11:00am30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
FAST - Unlocking GPCR Activating Antibodies with Library-scale Functional Data
- Monica Schwartz, Ph.D. - Vice President of Antibody Discovery, Abalone Bio
10:30am - 11:00am30 mins
Track 2: Unusual Antibody Formats
Antibody Engineering to Maximize the Clearance of Abundant Targets
- Sofie Voet, Ph.D. - Principal Scientist, Argenx
11:00am - 11:30am30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
A Novel, Label-free Assay to Determine the Binding Kinetics of Therapeutic Antibodies on Living Cells
- Eric Janezic, Ph.D. - Principal Scientist, Genentech
11:00am - 11:30am30 mins
Track 2: Unusual Antibody Formats
Dual Cell Bidirectional Antibodies for Treating Autoimmunity
- Jyothsna Visweswaraiah, PhD - Director, Biotherapeutics Drug Creation, Seismic Therapeutic
11:30am - 12:00pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
High Throughput Antibody-on-a-Chip Sequencing and Affinity Determination
- Curtis Layton, PhD - CEO and Co-Founder, Protillion Biosciences
11:30am - 12:00pm30 mins
Track 2: Unusual Antibody Formats
Converting IgG to IgM to Target Infectious Disease
- Remy Muts - PhD Candidate, UMC Utrecht
12:00pm - 12:30pm30 mins
Scientific Briefing 1
Optimizing Collaborations with AI Teams: A Primer for Scientists Exploring AI for Antibody Design
- Brett Averso - Chief Technology Officer, EVQLV
12:00pm - 12:30pm30 mins
Scientific Briefing 2
Advancing Discovery: Leveraging Hybrid-mechanistic Modeling for Development of a Robust mAb Platform Process
- Brian Berquist, PhD - SVP & Chief Development Officer, Wheeler Bio
12:00pm - 12:30pm30 mins
Scientific Briefing 3
High-Throughput Droplet Sorting Technology Accelerates Antibody Discovery
- Xin Yuan, PhD - Senior Scientist, DPBio
12:00pm - 12:30pm30 mins
Scientific Briefing 4
Deeper Therapeutic Antibody Developmental Insights via Comprehensive Fc Effector Function Profiling
- Shashi Jatiani, PhD - Director of Research, SeromYx Systems
12:00pm - 12:30pm30 mins
Scientific Briefing 5
Lightcast
12:30pm - 2:10pm100 mins
Networking Luncheon, Last Chance for Exhibit and Poster Viewing
2:10pm - 2:15pm5 mins
Track 1: Advanced In Vivo Antibody Discovery
Co-Chairs' Remarks - Advanced In Vivo Antibody Discovery
- Laura Walker, PhD - Head of Infectious Disease Biotherapeutics Discovery, Moderna
- Mitchell Ho, PhD - Senior Investigator, Laboratory of Molecular Biology, NIH NCI
2:10pm - 2:15pm5 mins
Track 2: Emerging Technologies for Antibody-Drug Conjugates
Co-Chairs’ Remarks - Emerging Technologies for Antibody-Drug Conjugates
- Thomas Pillow, PhD - Distinguished Scientist, Genentech
- Gregory Adams, PhD - Chief Scientific Officer, Elucida Oncology
2:15pm - 2:45pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Advanced Technologies to Screen and Engineer Immune Receptors
- Brandon DeKosky, Ph.D. - Assistant Professor of Chemical Engineering, MIT
2:15pm - 2:45pm30 mins
Track 2: Emerging Technologies for Antibody-Drug Conjugates
MYTX-011: A cMET-targeting ADC Engineered for Anti-tumor Activity Against a Broader Spectrum of cMET Expression
- Brian Fiske, Ph.D. - Chief Scientific Officer, Mythic Therapeutics
2:45pm - 3:15pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
In Vivo Affinity Maturation of Human Antibodies in Mice
- Yiming Yin, Ph.D. - Postdoctoral Research Fellow, Boston Children's Hospital
2:45pm - 3:15pm30 mins
Track 2: Emerging Technologies for Antibody-Drug Conjugates
Generation of Binder-Format-Payload Antibody Conjugate Matrices by Antibody Chain Exchange
- Ulrich Brinkmann - Expert Scientist, Large Molecule Research, Roche Innovation Center Munich
3:15pm - 3:45pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Identifying, Characterizing and Targeting Distinct Sources of IgE To Durably Reverse Allergy
- Jamie Orengo, Ph.D. - Vice President Research, Allergy and Immunity, Regeneron
3:15pm - 3:45pm30 mins
Track 2: Emerging Technologies for Antibody-Drug Conjugates
A Novel Dual-payload ADC Platform to Overcome Payload Resistance and Maximize Therapeutic Promise
- Jerome Boyd-Kirkup, PhD - Chief Scientific Officer and Co-Founder, Hummingbird Bioscience
3:45pm - 4:15pm30 mins
Networking Refreshment Break
4:15pm - 4:45pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
mRNA-encoded Bispecific Antibodies to Combat SARS-COV-2
- Anna Wec, PhD - Associate Director, Infectious Disease Research, Immunology, Moderna
4:15pm - 4:45pm30 mins
Track 2: Emerging Technologies for Antibody-Drug Conjugates
Tumor Targeting Therapies with CAPAC (Click Activated Protodrugs Against Cancer): A Novel Platform to Overcome Efficacy Limiting Toxicities Associated with ADCs
- Jose Mejia Oneto, M.D., Ph.D. - Founder & CEO, Shasqi
4:45pm - 5:15pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Characterization of Viral Antigen Supersites in Human Vaccine Studies
- Sarah Andrews, Ph.D. - Chief, B Cell Immunobiology Section, Vaccine Research Center, NIH
4:45pm - 5:15pm30 mins
Track 2: Emerging Technologies for Antibody-Drug Conjugates
Potentiation Strategies to Enhance the Efficacy of Radioimmunotherapy
- Marika Nestor, PhD - Professor in Biomedical Radiation Sciences, Uppsala University
5:15pm - 5:45pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Germinal Center B Cell Response to mRNA Vaccination in Humans
- Ali Ellebedy, Ph.D. - Leo Loeb Endowed Professor, Pathology & Immunology, Washington University School of Medicine
5:15pm - 5:45pm30 mins
Track 2: Emerging Technologies for Antibody-Drug Conjugates
Design and Evaluation of Fc-gamma Ablated TLR7 Agonist ADCs
- Anqi Zhang, PhD - Postdoctoral Fellow, Binghamton University
5:45pm - 5:50pm5 mins
Close of Conference
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。